

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input checked="" type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	11/1/2024

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Neuromuscular Electrical Stimulation (NMES)

Neuromuscular electrical stimulation (NMES) to treat muscle atrophy may be considered **medically necessary** when the following criteria are met:

- The nerve supply to the muscle is intact (including brain, spinal cord, and peripheral nerves); **and**
- The patient has any of the following conditions:
 - Previous casting or splinting of a limb; **or**
 - Contractures due to scarring from burns; **or**
 - Recent hip replacement surgery (until rehabilitation therapy begins); **or**
 - Previous major knee surgery (when there is failure to respond to rehabilitation therapy.)

Continued Use of Neuromuscular Electrical Stimulation (NMES)

Continued use of NMES may be considered medically necessary to treat muscular atrophy when **ALL** the following conditions have been met:

- Initial therapeutic trial
- Effectiveness
- Compliance has been demonstrated with the device used on a regular basis (i.e., daily or near daily use) throughout the trial period

Functional Neuromuscular Electrical Stimulation

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

To support independent ambulation, Functional Neuromuscular Electrical Stimulation for spinal cord injury (e.g. Parastep Ambulation System) may be considered **medically necessary** for patients with diagnosis of paraplegia and meet **ALL** of the following criteria:

- Intact lower motor units (L1 and below) (both muscle and peripheral nerve); **and**
- Muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently; **and**
- Demonstrate brisk muscle contraction to NMES; **and**
- Possess high motivation, commitment and cognitive ability to use such devices for walking; **and**
- Transfer independently and can demonstrate standing tolerance for at least 3 minutes; **and**
- Demonstrate hand and finger function to manipulate controls or have an attendant available that can manipulate the controls; **and**
- At least 6-month post recovery spinal cord injury and restorative surgery; **and**
- Without severe, untreated hip and knee degenerative disease that prohibits them from the joint range of motion necessary for ambulation and no history of long bone fracture secondary to osteoporosis; **and**
- Demonstrated a willingness to use the device long-term; **and**
- Have completed a training program which consists of physical medicine sessions with the device, (Parastep® Ambulation System) (typically over a period of three (3) months).

Functional neuromuscular electrical stimulation for spinal cord injury (e.g. Parastep Ambulation System) is contraindicated in the following instances:

- cardiac pacemakers
- severe scoliosis or severe osteoporosis
- skin disease or cancer at the area of stimulation
- irreversible contractures
- autonomic dysreflexia

All other types of Functional Neuromuscular Electrical Stimulation devices and uses, including but not limited to, foot drop, stroke, multiple sclerosis or cerebral palsy, are considered **investigational**.

There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure for the above indications.

Cross-references:

MP-6.020 Transcutaneous Electrical Nerve Stimulation

MP-6.045 Sympathetic Therapy for the Treatment of Pain

MP-6.046 Threshold Electrical Stimulation as a Treatment of Motor Disorders

MP-6.047 Interferential Current Stimulation

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

MP-6.048 Electrical Stimulation for the Treatment of Arthritis and Miscellaneous Conditions

MP-6.049 H-Wave Electrical Stimulation

MP-6.050 Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO- Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[TOP](#)

Neuromuscular electrical stimulation (NMES)

NMES involves the use of a device that transmits electrical impulse to the skin over selected muscle groups by way of electrodes. The NMES device encompasses a portable stimulator with electrodes that are placed on the skin over a targeted muscle or muscle group. The current passes through the electrodes into the body, and the motor nerves are stimulated, causing a muscle contraction. The intensity and frequency of stimulation can vary based on the level of muscular function and response to treatment. There are two categories of NMES. One is used to treat muscle atrophy and stimulates the muscle when the individual is in a resting state. The other, also known as functional electrical stimulation (FES), is used to enhance functional activity of neurologically impaired and spinal cord injured (SCI) patients.

Functional electrical stimulation

Functional electrical stimulation (FES) involves the use of an orthotic device or exercise equipment with microprocessor-controlled electrical muscular stimulation. These devices are being developed to restore function and improve health in patients with damaged or destroyed nerve pathways (e.g., spinal cord injury [SCI], stroke, multiple sclerosis, cerebral palsy).

FES is an approach to rehabilitation that applies low-level electrical current to stimulate functional movements in muscles affected by nerve damage. It focuses on the restoration of useful movements, like standing, stepping, pedaling for exercise, reaching, or grasping.

FES devices consist of an orthotic and a microprocessor-based electronic stimulator with one or more channels for delivery of individual pulses through surface or implanted electrodes connected to the neuromuscular system. Microprocessor programs activate the channels sequentially or in unison to stimulate peripheral nerves and trigger muscle contractions to

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

produce functionally useful movements that allow patients to sit, stand, walk, cycle, or grasp. Functional neuromuscular stimulators are closed-loop systems that provide feedback information on muscle force and joint position, thus allowing constant modification of stimulation parameters, which are required for complex activities (e.g., walking). These systems are contrasted with open-loop systems, which are used for simple tasks (e.g., muscle strengthening alone); healthy individuals with intact neural control benefit the most from this technology.

Applications, described in more detail in the Rationale section, include upper extremity grasping function after spinal cord injury and stroke, lifting the front of the foot during ambulation in individuals with footdrop, and ambulation and exercise for patients with spinal cord injury. Some devices are used primarily for rehabilitation rather than home use. This evidence review focuses on devices intended for home use.

Regulatory Status

A variety of FES devices have been cleared by the U.S. Food and Drug Administration (FDA) and are available for home use. Table 1 provides examples of devices designed to improve hand and foot function as well as cycle ergometers for home exercise. The date of the FDA clearance is for the first 510(k) clearance identified for a marketed device. Many devices have additional FDA clearances as the technology evolved, each in turn listing the most recent device as the predicate.

Table 1. Functional Electrical Stimulation Devices Cleared by the FDA

Device	Manufacturer	Device Type	Clearance	Date	Product Code
NESS H200® (previously Handmaster)	Bioness	Hand stimulator	K022776	2001	GZC
MyndMove System	MyndTec	Hand stimulator	K170564	2017	GZI/IPF
ReGrasp	Rehabtronics	Hand stimulator	K153163	2016	GZI/IPF
WalkAide® System	Innovative Neurotronics (formerly NeuroMotion)	Foot drop stimulator	K052329	2005	GZI
ODFS® (Odstock Dropped Foot Stimulator)	Odstock Medical	Foot drop stimulator	K050991	2005	GZI
ODFS® Pace XL	Odstock Medical	Foot drop stimulator	K171396	2018	GZI/IPF
L300 Go	Bioness	Foot drop stimulator	K190285	2019	GZI/IPF

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

L100 Go	Bioness	Foot drop stimulator	K200262	2020	GZI/IPF
Foot Drop System	SHENZHEN XFT Medical	Foot drop stimulator	K162718	2017	GZI
Nerve And Muscle Stimulator	SHENZHEN XFT Medical	Foot drop stimulator	K193276	2020	GZI
MyGait® Stimulation System	Otto Bock HealthCare	Foot drop stimulator	K141812	2015	GZI
MStim Drop Model LGT-233	Guangzhou Longest Science & Technology	Foot drop stimulator	K202110	2021	GZI/IPF
ERGYS (TTI Rehabilitation Gym)	Therapeutic Alliances	Leg cycle ergometer	K841112	1984	IPF
RT300	Restorative Therapies, Inc (RTI)	Cycle ergometer	K050036	2005	GZI
Myocycle Home	Myolyn	Cycle ergometer	K170132	2017	GZI
Cionic Neural Sleeve NS-100	Cionic	Foot drop stimulator	K221823	2022	GZI/IPF
EvoWalk 1.0	Evolution Devices Inc	Foot drop stimulator	K230997	2023	GZI

FDA: Food and Drug Administration.

To date, the Parastep® Ambulation System (Sigmedics) is the only noninvasive functional walking neuromuscular stimulation device to receive premarket approval from the FDA. The Parastep® device is approved to “enable appropriately selected skeletally mature spinal cord injured patients (level C6-T12) to stand and attain limited ambulation and/or take steps, with assistance if required, following a prescribed period of physical therapy training in conjunction with rehabilitation management of spinal cord injury.” FDA product code: MKD.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have loss of hand and upper-extremity function due to SCI or stroke who receive FES, the evidence includes a few small case series and a randomized controlled trial (RCT). Relevant outcomes are functional outcomes and quality of life. Interpretation of the evidence is limited by the low number of patients studied and lack of data demonstrating the utility of FES outside the investigational setting. It is uncertain whether FES can restore some

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

upper-extremity function or improve the quality of life. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who have chronic foot drop who receive FES, the evidence includes RCTs, meta-analyses, and a longitudinal cohort study. Relevant outcomes are functional outcomes and quality of life. For chronic poststroke foot drop, 2 RCTs comparing FES with a standard ankle-foot orthosis (AFO) showed improved patient satisfaction with FES but no significant differences between groups in objective measures such as walking. Another RCT found no significant differences between use versus no use of FES on walking outcomes. Similarly, one meta-analysis found no difference between AFO and FES in walking speed, and another meta-analysis found no difference between FES and conventional treatments. The cohort study assessed patients' ability to avoid obstacles while walking on a treadmill using FES versus AFO. Although the FES group averaged a 4.7% higher rate of avoidance, the individual results between devices ranged widely. One RCT with 53 subjects examining neuromuscular stimulation for foot drop in patients with multiple sclerosis showed a reduction in falls and improved patient satisfaction compared with an exercise program but did not demonstrate a clinically significant benefit in walking speed. Another RCT showed that at 12 months, both FES and AFO had improved walking speed, but the difference in improvement between the 2 devices was not significant. Another study found FES (combined with postural correction) and neuroproprioceptive facilitation and inhibition physiotherapy did not differ in walking speed or balance immediately or 2 months after program end. A reduction in falls is an important health outcome. However, it was not a primary study outcome and should be corroborated. The literature on FES in children with cerebral palsy includes 3 systematic reviews of small studies with within-subject designs. All included studies only measure short-term results; it is unclear what the long-term effects of FES may be in this population. Further study is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have SCI at segments T4 to T12 who receive FES, the evidence includes case series. Relevant outcomes are functional outcomes and quality of life. No controlled trials were identified on FES for standing and walking in patients with SCI. However, case series are considered adequate for this condition because there is no chance for unaided ambulation in this population with SCI at this level. Some studies have reported improvements in intermediate outcomes, but improvements in health outcomes (e.g., ability to perform activities of daily living, quality of life) have not been demonstrated.

For individuals who have SCI who receive FES exercise equipment, the evidence includes prospective comparisons. The relevant outcomes are symptoms, functional outcomes, and quality of life. The evidence on FES exercise equipment consists primarily of within-subject pretreatment to posttreatment comparisons. Evidence was identified on 2 commercially available FES cycle ergometer models for the home, the RT300 series and the REGYS/ERGYS series. There is a limited amount of evidence on the RT300 series. None of the within-subject studies showed an improvement in health benefits, however, improvement in body fat with RT300 was found in a small group of patients when FES high intensity interval cycling was

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

added to nutrition counseling compared to nutritional counseling alone. One analysis of use for 314 individuals over 20,000 activity sessions with a Restorative Therapies device showed that a majority of users used the device for 34 minutes per week. Two percent of individuals with SCI used the device for an average of six days per week, but caloric expenditure remained low. Compliance was shown in one study to be affected by the age of participants and level of activity prior to the study. Studies on the REGYS/ERGYS series have more uniformly shown an improvement in physiologic measures of health and in sensory and motor function; however, a small comparative study found arm cycling to improve exercise energy expenditure and cardiorespiratory fitness to a greater extent than FES leg cycling. A limitation of these studies is that they all appear to have been conducted in supervised in research centers. No studies were identified on long-term home use of ERGYS cycle ergometers. The feasibility and long-term health benefits of using this device in the home is uncertain.

V. DEFINITIONS

[TOP](#)

510 (k) is a premarketing submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device that is not subject to premarket approval (PMA). Applicants must compare their 510(k) device to one or more similar devices currently on the U.S. market and make and support their substantial equivalency claims.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

Procedure Codes							
A4560	E0745	E0764					

Investigational; therefore, not covered:

Procedure Codes							
E0770							

ICD-10-CM Diagnosis Code	Description
G82.20	Paraplegia, unspecified
G82.21	Paraplegia, complete
G82.22	Paraplegia, incomplete
M62.50	Muscle wasting and atrophy, not elsewhere classified, unspecified site
M62.511	Muscle wasting and atrophy, not elsewhere classified, right shoulder
M62.512	Muscle wasting and atrophy, not elsewhere classified, left shoulder
M62.519	Muscle wasting and atrophy, not elsewhere classified, unspecified shoulder
M62.521	Muscle wasting and atrophy, not elsewhere classified, right upper arm
M62.522	Muscle wasting and atrophy, not elsewhere classified, left upper arm
M62.529	Muscle wasting and atrophy, not elsewhere classified, unspecified upper arm
M62.531	Muscle wasting and atrophy, not elsewhere classified, right forearm
M62.532	Muscle wasting and atrophy, not elsewhere classified, left forearm
M62.539	Muscle wasting and atrophy, not elsewhere classified, unspecified forearm
M62.541	Muscle wasting and atrophy, not elsewhere classified, right hand
M62.542	Muscle wasting and atrophy, not elsewhere classified, left hand
M62.549	Muscle wasting and atrophy, not elsewhere classified, unspecified hand
M62.551	Muscle wasting and atrophy, not elsewhere classified, right thigh
M62.552	Muscle wasting and atrophy, not elsewhere classified, left thigh
M62.559	Muscle wasting and atrophy, not elsewhere classified, unspecified thigh
M62.561	Muscle wasting and atrophy, not elsewhere classified, right lower leg
M62.562	Muscle wasting and atrophy, not elsewhere classified, left lower leg

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

ICD-10-CM Diagnosis Code	Description
M62.569	Muscle wasting and atrophy, not elsewhere classified, unspecified lower leg
M62.571	Muscle wasting and atrophy, not elsewhere classified, right ankle and foot
M62.572	Muscle wasting and atrophy, not elsewhere classified, left ankle and foot
M62.579	Muscle wasting and atrophy, not elsewhere classified, unspecified ankle and foot
M62.58	Muscle wasting and atrophy, not elsewhere classified, other site
M62.59	Muscle wasting and atrophy, not elsewhere classified, multiple sites
M62.5A0	Muscle wasting and atrophy, not elsewhere classified, back, cervical
M62.5A1	Muscle wasting and atrophy, not elsewhere classified, back, thoracic
M62.5A2	Muscle wasting and atrophy, not elsewhere classified, back, lumbosacral
M62.5A9	Muscle wasting and atrophy, not elsewhere classified, back, unspecified level
Z47.1	Aftercare following joint replacement surgery

IX. REFERENCES

[TOP](#)

1. Centers for Medicare & Medicaid Services. *Decision Memo for Neuromuscular Electrical Stimulation (NMES) for Spinal Cord Injury (CAG-00153R)*. 2002
2. Mulcahey MJ, Betz RR, Kozin SH, et al. *Implantation of the Freehand System during initial rehabilitation using minimally invasive techniques*. *Spinal Cord*. Mar 2004;42(3):146-155. PMID 15001979
3. Mulcahey MJ, Betz RR, Smith BT, et al. *Implanted functional electrical stimulation hand system in adolescents with spinal injuries: an evaluation*. *Arch Phys Med Rehabil*. Jun 1997;78(6):597-607. PMID 9196467
4. Taylor P, Esnouf J, Hobby J. *The functional impact of the Freehand System on tetraplegic hand function*. *Clinical Results*. *Spinal Cord*. Nov 2002;40(11):560-566. PMID 12411963
5. Venugopalan L, Taylor PN, Cobb JE, et al. *Upper limb functional electrical stimulation devices and their man- machine interfaces*. *J Med Eng Technol*. Oct 2015;39(8):471-479. PMID 26508077
6. Alon G, McBride K. *Persons with C5 or C6 tetraplegia achieve selected functional gains using a neuroprosthesis*. *Arch Phys Med Rehabil*. Jan 2003;84(1):119-124. PMID 12589632
7. Alon G, McBride K, Ring H. *Improving selected hand functions using a noninvasive neuroprosthesis in persons with chronic stroke*. *J Stroke Cerebrovasc Dis*. Mar-Apr 2002;11(2):99-106. PMID 17903863
8. Snoek GJ, IJzerman MJ, in 't Groen FA, et al. *Use of the NESS handmaster to restore handfunction in tetraplegia: clinical experiences in ten patients*. *Spinal Cord*. Apr 2000;38(4):244-249. PMID 10822395
9. Anderson KD, Korupolu R, Musselman KE, et al. *Multi-center, single-blind randomized controlled trial comparing functional electrical stimulation therapy to conventional therapy in incomplete tetraplegia*. *Front Rehabil Sci*. 2022; 3: 995244. PMID 36188946

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

10. Jaqueline da Cunha M, Rech KD, Salazar AP, et al. Functional electrical stimulation of the peroneal nerve improves post-stroke gait speed when combined with physiotherapy. A systematic review and meta-analysis. *Ann Phys Rehabil Med.* Jan 2021; 64(1): 101388. PMID 32376404
11. Nascimento LR, da Silva LA, Araujo Barcellos JVM, et al. Ankle-foot orthoses and continuous functional electrical stimulation improve walking speed after stroke: a systematic review and meta-analyses of randomized controlled trials. *Physiotherapy.* Dec 2020; 109: 43-53. PMID 33120054
12. Hachisuka K, Ochi M, Kikuchi T, et al. Clinical effectiveness of peroneal nerve functional electrical stimulation in chronic stroke patients with hemiplegia (PLEASURE): A multicentre, prospective, randomised controlled trial. *Clin Rehabil.* Oct 26 2020: 269215520966702. PMID 33103916
13. Bethoux F, Rogers HL, Nolan KJ, et al. The effects of peroneal nerve functional electrical stimulation versus ankle-foot orthosis in patients with chronic stroke: a randomized controlled trial. *Neurorehabil Neural Repair.* Sep 2014;28(7):688-697. PMID 2452670
14. Kluding PM, Dunning K, O'Dell MW, et al. Foot drop stimulation versus ankle foot orthosis after stroke: 30-week outcomes. *Stroke.* Jun 2013;44(6):1660-1669. PMID 23640829
15. O'Dell MW, Dunning K, Kluding P, et al. Response and prediction of improvement in gait speed from functional electrical stimulation in persons with poststroke drop foot. *PM R.* Jul 2014; 6(7): 587-601; quiz 601. PMID 24412265
16. Berenpas F, Geurts AC, den Boer J, et al. Surplus value of implanted peroneal functional electrical stimulation over ankle-foot orthosis for gait adaptability in people with foot drop after stroke. *Gait Posture.* Jun 2019; 71: 157-162. PMID 31071538
17. Prokopiusova T, Pavlikova M, Markova M, et al. Randomized comparison of functional electric stimulation in posturally corrected position and motor program activating therapy: treating foot drop in people with multiple sclerosis. *Eur J Phys Rehabil Med.* Aug 2020; 56(4): 394-402. PMID 32383574
18. Renfrew LM, Paul L, McFadyen A, et al. The clinical- and cost-effectiveness of functional electrical stimulation and ankle-foot orthoses for foot drop in Multiple Sclerosis: a multicentre randomized trial. *Clin Rehabil.* Jul 2019; 33(7): 1150-1162. PMID 30974955
19. Barrett CL, Mann GE, Taylor PN, et al. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. *Mult Scler.* Apr 2009;15(4):493-504. PMID 19282417
20. Esnouf JE, Taylor PN, Mann GE, et al. Impact on activities of daily living using a functional electrical stimulation device to improve dropped foot in people with multiple sclerosis, measured by the Canadian Occupational Performance Measure. *Mult Scler.* Sep 2010;16(9):1141-1147. PMID 20601398
21. Cauraugh JH, Naik SK, Hsu WH, et al. Children with cerebral palsy: a systematic review and meta-analysis on gait and electrical stimulation. *Clin Rehabil.* Nov 2010;24(11):963-978. PMID 20685722
22. Zhu Q, Gao G, Wang K, et al. Effect of Functional Electrical Stimulation on Gait Parameters in Children with Cerebral Palsy: A Meta-Analysis. *Comput Math Methods Med.* 2022; 2022: 3972958. PMID 36238472

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

23. Chen YH, Wang HY, Liao CD, et al. Effectiveness of neuromuscular electrical stimulation in improving mobility in children with cerebral palsy: A systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil.* Jan 2023; 37(1): 3-16. PMID 35730135
24. Chaplin E. Functional neuromuscular stimulation for mobility in people with spinal cord injuries. *The Parastep I System. J Spinal Cord Med.* Apr 1996;19(2):99-105. PMID 8732878
25. Klose KJ, Jacobs PL, Broton JG, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 1. Ambulation performance and anthropometric measures. *Arch Phys Med Rehabil.* Aug 1997;78(8):789-793. PMID 9344294
26. Jacobs PL, Nash MS, Klose KJ, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 2. Effects on physiological responses to peak arm ergometry. *Arch Phys Med Rehabil.* Aug 1997;78(8):794-798. PMID 9344295
27. Needham-Shropshire BM, Broton JG, Klose KJ, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 3. Lack of effect on bone mineral density. *Arch Phys Med Rehabil.* Aug 1997;78(8):799-803. PMID 9344296
28. Guest RS, Klose KJ, Needham-Shropshire BM, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 4. Effect on physical self-concept and depression. *Arch Phys Med Rehabil.* Aug 1997;78(8):804-807. PMID 9344297
29. Nash MS, Jacobs PL, Montalvo BM, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 5. Lower extremity blood flow and hyperemic responses to occlusion are augmented by ambulation training. *Arch Phys Med Rehabil.* Aug 1997;78(8):808-814. PMID 9344298
30. Graupe D, Kohn KH. Functional neuromuscular stimulator for short-distance ambulation by certain thoracic-level spinal-cord-injured paraplegics. *Surg Neurol.* Sep 1998;50(3):202-207. PMID 9736079
31. Brissot R, Gallien P, Le Bot MP, et al. Clinical experience with functional electrical stimulation-assisted gait with Parastep in spinal cord-injured patients. *Spine (Phila Pa 1976).* Feb 15 2000;25(4):501-508. PMID 10707398
32. Sykes L, Ross ER, Powell ES, et al. Objective measurement of use of the reciprocating gait orthosis (RGO) and the electrically augmented RGO in adult patients with spinal cord lesions. *Prosthet Orthot Int.* Dec 1996; 20(3): 182-90. PMID 8985998
33. Davis JA, Triolo RJ, Uhler J, et al. Preliminary performance of a surgically implanted neuroprosthesis for standing and transfers--where do we stand?. *J Rehabil Res Dev.* Nov-Dec 2001; 38(6): 609-17. PMID 11767968
34. Rohde LM, Bonder BR, Triolo RJ. Exploratory study of perceived quality of life with implanted standing neuroprostheses. *J Rehabil Res Dev.* 2012; 49(2): 265-78. PMID 22773528
35. Triolo RJ, Bailey SN, Miller ME, et al. Longitudinal performance of a surgically implanted neuroprosthesis for lower-extremity exercise, standing, and transfers after spinal cord injury. *Arch Phys Med Rehabil.* May 2012; 93(5): 896-904. PMID 22541312
36. U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion. *Physical activity guidelines, second edition.*

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

37. Hunt, KK, Fang, JJ, Saengsuwan, JJ, Grob, MM, Laubacher, MM. On the efficiency of FES cycling: a framework and systematic review. *Technol Health Care*, 2012 Oct 20;20(5). PMID 23079945
38. Ralston, KK, Harvey, LL, Batty, JJ, Bonsan, LL, Ben, MM, Cusmiani, RR, Bennett, JJ. Functional electrical stimulation cycling has no clear effect on urine output, lower limb swelling, and spasticity in people with spinal cord injury: a randomised cross-over trial. *J Physiother*, 2013 Nov 30;59(4). PMID 24287217
39. Dolbow, DD, Gorgey, AA, Ketchum, JJ, Gater, DD. Home-based functional electrical stimulation cycling enhances quality of life in individuals with spinal cord injury. *Top Spinal Cord Inj Rehabil*, 2013 Nov 19;19(4). PMID 24244097.
40. Dolbow, DD, Gorgey, AA, Ketchum, JJ, Moore, JJ, Hackett, LL, Gater, DD. Exercise adherence during home-based functional electrical stimulation cycling by individuals with spinal cord injury. *Am J Phys Med Rehabil*, 2012 Oct 23;91(11). PMID 23085704
41. Johnston, TT, Smith, BB, Mulcahey, MM, Betz, RR, Lauer, RR. A randomized controlled trial on the effects of cycling with and without electrical stimulation on cardiorespiratory and vascular health in children with spinal cord injury. *Arch Phys Med Rehabil*, 2009 Aug 5;90(8). PMID 19651272
42. Dolbow DR, Credeur DP, Lemacks JL, et al. Electrically induced cycling and nutritional counseling for counteracting obesity after spinal cord injury: A pilot study. *J Spinal Cord Med*. Jul 2021; 44(4): 533-540. PMID 31971487
43. Sadowsky, CC, Hammond, EE, Strohl, AA, Commean, PP, Eby, SS, Damiano, DD, Wingert, JJ, Bae, KK, McDonald, JJ. Lower extremity functional electrical stimulation cycling promotes physical and functional recovery in chronic spinal cord injury. *J Spinal Cord Med*, 2013 Oct 8;36(6). PMID 24094120
44. Griffin, LL, Decker, MM, Hwang, JJ, Wang, BB, Kitchen, KK, Ding, ZZ, Ivy, JJ. Functional electrical stimulation cycling improves body composition, metabolic and neural factors in persons with spinal cord injury. *J Electromyogr Kinesiol*, 2008 Apr 29;19(4). PMID 18440241
45. Farkas GJ, Gorgey AS, Dolbow DR, et al. Energy Expenditure, Cardiorespiratory Fitness, and Body Composition Following Arm Cycling or Functional Electrical Stimulation Exercises in Spinal Cord Injury: A 16-Week Randomized Controlled Trial. *Top Spinal Cord Inj Rehabil*. 2021; 27(1): 121-134. PMID 33814890
46. Kressler J, Ghersin H, Nash MS. Use of functional electrical stimulation cycle ergometers by individuals with spinal cord injury. *Top Spinal Cord Inj Rehabil*. 2014; 20(2): 123-6. PMID 25477734
47. National Institute for Health and Care Excellence (NICE). *Functional electrical stimulation for drop foot of central neurological origin [IPG278]*. 2009
48. Kressler, JJ, Ghersin, HH, Nash, MM. Use of functional electrical stimulation cycle ergometers by individuals with spinal cord injury. *Top Spinal Cord Inj Rehabil*, 2014 Dec 6;20(2). PMID 25477734
49. Centers for Medicare & Medicaid Services. *National Coverage Determination (NCD) for Neuromuscular Electrical Stimulaton (NMES) (160.12)*. 2006
50. Barkoudah, E., Glader, L. Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues. In: *UpToDate Online Journal [serial online]*. Waltham, MA: UpToDate; updated November 17, 2023

MEDICAL POLICY

POLICY TITLE	NEUROMUSCULAR AND FUNCTIONAL NEUROMUSCULAR ELECTRICAL STIMULATION
POLICY NUMBER	MP 6.051

51. Doucet, B. M., Lam, A., & Griffin, L. (2012). Neuromuscular electrical stimulation for skeletal muscle function. *The Yale journal of biology and medicine*. 2012 June; 85(2), 201–215
52. Fehlings MG, Tetreault LA, Aarabi B, et al. A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Type and Timing of Rehabilitation. *Global Spine J*. 2017;7(3 Suppl):231S-238S. PMID: 29164029
53. Ho CH, Triolo RJ, Elias AL, et al. Functional electrical stimulation and spinal cord injury. *Phys Med Rehabil Clin N Am*. 2014;25(3):631-ix. doi: 10.1016/j.pmr.2014.05.001. PMID: 25064792
54. Blue Cross Blue Shield Association Medical Policy Reference Manual. 8.03.01, Functional Neuromuscular Electrical Stimulation. April 2024

Other Sources:

Taber’s Cyclopedic Medical Dictionary, 19th edition

X. POLICY HISTORY

[TOP](#)

MP 6.051	06/24/2020 Consensus Review. Policy statement unchanged. Product variation, benefit variation, disclaimer, coding, and references updated.
	06/18/2021 Consensus Review. Policy statement unchanged. Revised Summary of evidence and Table 1. Removed diagnosis codes M62.52 and M62.56. References added.
	06/24/2022 Minor Review. Functional Neuromuscular Electrical Stimulation (FNES) changed from E/I to medically necessary with criteria for spinal cord injury. Contraindications for FNES also listed. Added ICD10 codes G82.20, G82.21 and G82.22. FEP language updated. Rationale revised. References added.
	08/15/2022 Administrative Update. ICD10 codes M62.5A0, M62.5A1, M62.5A2 and M62.5A3 added to policy; effective 10/1/2022.
	03/16/2023 Administrative Update New Code A4560 added Effective 4/1/23.
	05/19/2023 Consensus Review. No change to policy statement. Product Variation statement, Background and Rationale updated. References added.
	04/26/2024 Minor review. Criteria for NMES continued use added. Background and References updated.

[TOP](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.